Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 351 to 400 of 2559

TitleReference numberPublishedLast updated
ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessmentHTG664
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedemaTA953
Dupilumab for treating moderate to severe prurigo nodularisTA955
Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and overTA956
Lung cancer: diagnosis and managementNG122
Digital technologies for delivering multidisciplinary weight-management services: early value assessmentHTG700
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatmentsTA954
Vitamin B12 deficiency in over 16s: diagnosis and managementNG239
Endoscopic sleeve gastroplasty for obesityHTG711
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutationsTA952
TuberculosisNG33
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overTA950
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)TA945
Devices for remote monitoring of Parkinson's diseaseHTG657
COVID-19 rapid guideline: managing the long-term effects of COVID-19NG188
Skin cancerQS130
Neonatal infectionQS75
Pharyngeal electrical stimulation for neurogenic dysphagiaHTG709
Temperature control to improve neurological outcomes after cardiac arrestHTG710
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Sebelipase alfa for treating Wolman diseaseHST30
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Intravascular lithotripsy for calcified arteries in peripheral arterial diseaseHTG707
Epilepsies in children, young people and adultsQS211
Empagliflozin for treating chronic kidney diseaseTA942
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Transition from children's to adults' servicesQS140
Digitally enabled therapies for adults with anxiety disorders: early value assessmentHTG676
Middle meningeal artery embolisation for chronic subdural haematomasHTG706
Cardiovascular disease: risk assessment and reduction, including lipid modificationNG238
Velmanase alfa for treating alpha-mannosidosisHST29
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolismHTG705
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932
Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosisHTG704
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Transient loss of consciousness ('blackouts') in over 16sCG109
Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessmentHTG701

Results per page

  1. 10
  2. 25
  3. 50
  4. All